Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/1/2022 | $11.00 | Buy | Jefferies |
| 11/19/2021 | $12.00 → $11.00 | Buy | HC Wainwright & Co. |
Company to host conference call and webcast on Thursday, March 27th at 8:30am EDT AUSTIN, Texas, March 6, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024, before the markets open on Thursday, March 27th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Da
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Fran Schulz, a highly experienced biotechnology and financial executive, to the Senti Bio Board of Directors ("Board"). "We are excited to welcome Fran to the Senti Bio Board of Directors," said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio. "Fran's deep expertise in the life sciences industry—spanning finance, strategic planning, operations, and transactions—wi
Reported Q3 worldwide revenue of EUR 13.1 million (USD 14.4 million), increasing 11.6% over Q3 2023Reported Q3 worldwide HIFU revenue of EUR 4.5 million (USD 4.9 million), increasing 48.2% over Q3 202334% year-over-year growth in U.S. Focal One HIFU procedures CMS increases Medicare Hospital Outpatient Focal One HIFU procedure payment by 5.4% for 2025Announced AI collaboration with Avenda Health for Focal One Robotic HIFUCompany to host conference call and webcast today, November 7th, at 8:30 a.m. EDT LYON, France, November 7, 2024 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the thi
SC 13G/A - EDAP TMS SA (0001041934) (Subject)
SC 13G/A - EDAP TMS SA (0001041934) (Subject)
SC 13G/A - EDAP TMS SA (0001041934) (Subject)
6-K - EDAP TMS SA (0001041934) (Filer)
6-K - EDAP TMS SA (0001041934) (Filer)
6-K - EDAP TMS SA (0001041934) (Filer)
Jefferies initiated coverage of EDAP TMS SA with a rating of Buy and set a new price target of $11.00
HC Wainwright & Co. reiterated coverage of Edap TMS with a rating of Buy and set a new price target of $11.00 from $12.00 previously
Piper Sandler initiated coverage of Edap TMS with a rating of Overweight and set a new price target of $13.00
Company to host conference call and webcast on Thursday, March 27th at 8:30am EDT AUSTIN, Texas, March 6, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024, before the markets open on Thursday, March 27th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Da
PDF Version LYON, France, March 3, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company" or "EDAP"), the global leader in robotic energy-based therapies, today announced the appointment of Glen French to its Board of Directors. "We are pleased to welcome Glen to our Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS. "Glen is a highly accomplished executive with extensive business and clinical expertise in the development of innovative new medical devices and technology, and his presence on our Board of Directors will help guide our strategic decision-making as we establish Focal One as the world's premier robotic HIFU technology platform."
First Focal One® procedure utilizing Cortechs.ai's advanced MRI-imaging technology, OnQ Prostate, successfully performed at the University of California, San Francisco Prostate Cancer CenterOnQ Prostate's Restriction Spectrum Imaging (RSI) technology improves lesion localization and targeting for urologists performing Focal One Robotic High Intensity Focused Ultrasound (HIFU) ablation Reflects EDAP's continued commitment to innovation and further validates Focal One as the leading focal therapy platform controlled by urologists San Diego, CA and Austin, Texas, February 6, 2025 - Cortechs.ai, an emerging leader in novel imaging solutions for prostate cancer care, and EDAP TMS SA (NASDAQ:E
PDF Version AUSTIN, Texas, January 10, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company" or "EDAP"), the global leader in robotic energy-based therapies, today announced the appointment of Joshua H. Levine to its Board of Directors. "We are pleased to welcome Josh Levine to our Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS. "Josh brings a wealth of executive experience and a track record of growing shareholder value by focusing on transformative, high growth business strategies within the medical technology sector. As EDAP continues to grow the market for its leading Focal One robotic HIFU platform, Josh will help shape our strategic vision and ex
PDF Version LYON, France, July 8, 2024 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company" or "EDAP"), the global leader in robotic energy-based therapies, today announced the appointment of Fran Schulz to its Board of Directors. "We are pleased to welcome Fran Schulz to our Board of Directors," said Marc Oczachowski, Chairman of the Board of EDAP TMS. "Fran brings a wealth of executive experience in the healthcare industry, and her expertise spans across a broad array of strategic finance and accounting functions. She also possesses an in-depth understanding of U.S. and international regulatory issues, which will further strengthen our Board's leadership as we continue to expand Focal One global
New appointments bring significant commercial experience with a focus on growing key strategic markets Expands executive leadership in growing disruptive, robotics-based capital equipment in both Urology and Gynecology therapeutic applications LYON, France, June 3, 2024 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, today announced the appointments of Damien Desmedt and Alexander Fromm to further strengthen the Company's European and Middle Eastern commercial leadership. Mr. Desmedt has been appointed Vice President of Sales for Europe, Middle East, Africa, and India (EMEAI), and Mr. Fromm has been appointed General Manager for Switzerland and will